Author | Elise Oberliesen


Oral Medication Option May Lead to Improved Treatment Adherence in Patients with Psoriatic Arthritis

September 04, 2014

Until apremilast was approved earlier this year, patients with psoriatic arthritis had to rely primarily on injectable therapies, which contributed to less than optimal treatment adherence in many patients.

Phase III Trial Results Show Certolizumab Pegol Is an Effective Treatment for Psoriatic Arthritis

August 25, 2014

Patients treated with certolizumab pegol for 24 weeks showed rapid improvement in the signs and symptoms of psoriatic arthritis.

Apremilast and the Future of Psoriatic Arthritis Treatment

August 21, 2014

When it was approved by the FDA in March 2014, apremilast became the first oral medication approved for the treatment of psoriatic arthritis (PsA). Data from clinical trials showed it to be an effective option for patients, with a safer side effect profile than currently used PsA treatments.

Tumor Necrosis Factor Inhibitors in the Treatment of Pediatric Psoriatic Arthritis

July 09, 2014

Study results show that treatment with etanercept is effective and well tolerated in adolescent patients with psoriatic arthritis and other rheumatic conditions.